Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.59 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | KLK7 | P49862 | 2/20 | 0.48 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.48 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | CETP | P11597 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5637318 | 1.00 | NR1H2 (0.59) | NR1H2NR1H3ABCB1DPP4HDAC1 | |
| SCHEMBL271604 | 1.00 | NR1H2 (0.59) | NR1H2NR1H3ABCB1DPP4HDAC1 | |
| SCHEMBL13323340 | 0.92 | PARP1 (0.54) | NR1H2NR1H3ABCB1DPP4HDAC1 | |
| SCHEMBL26967075 | 0.91 | NR1H2 (0.53) | NR1H2NR1H3ABCB1DPP4HDAC1 | |
| SCHEMBL14457265 | 0.89 | NR1H2 (0.51) | NR1H2NR1H3ABCB1DPP4HDAC1 | |
| SCHEMBL14457264 | 0.89 | NR1H2 (0.51) | NR1H2NR1H3ABCB1DPP4HDAC1 | |
| SCHEMBL16080305 | 0.89 | NR1H2 (0.51) | NR1H2NR1H3ABCB1DPP4HDAC1 | |
| SCHEMBL18936258 | 0.88 | NR1H2 (0.50) | NR1H2NR1H3ABCB1DPP4HDAC1 | |
| SCHEMBL18935776 | 0.88 | NR1H2 (0.50) | NR1H2NR1H3ABCB1DPP4HDAC1 | |
| SCHEMBL28334140 | 0.87 | NR1H2 (0.56) | NR1H2NR1H3ABCB1DPP4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741938-B2 | Compounds that are useful for improving pharmacokinetics | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130317071-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | ABBVIE INC (US) | 2013-11-28 | — | — | US | disclosed |
| US-8524753-B2 | Compounds that are useful for improving pharmacokinetics | ABBVIE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120184559-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | ABBOTT LABORATORIES (US) | 2012-07-19 | — | — | US | disclosed |
| US-8133892-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100280248-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | US | disclosed |
| US-7786153-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1993820-A2 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | Abbott Laboratories (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007103670-A2 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | ABBOTT LABORATORIES (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | ABBVIE INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184559-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | CYP11B1, CYP11B2, CYP7A1 | NR1H2 233/4885NR1H3 211/4885ABCB1 79/4885 |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | CYP11B1, CYP11B2, CYP7A1 | NR1H2 233/4885NR1H3 211/4885ABCB1 79/4885 |
| US-20100280248-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | CYP11B1, CYP11B2, CYP7A1 | NR1H2 233/4885NR1H3 211/4885ABCB1 79/4885 |
| US-20130317071-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | CYP11B1, CYP11B2, CYP7A1 | NR1H2 233/4885NR1H3 211/4885ABCB1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.